CytoSorbents gets Nasdaq bid-price extension

CytoSorbents Corporation received a 180-day extension from Nasdaq, until September 28, 2026, to regain compliance with the $1.00 minimum bid price requirement for its common stock.

Rhea-AI Filing Summary

CytoSorbents Corporation received a 180-day extension from Nasdaq, until September 28, 2026, to regain compliance with the $1.00 minimum bid price requirement for its common stock. The company will regain compliance if its share price closes at or above $1.00 for at least 10 consecutive trading days before that date.

The notice has no immediate effect on the Nasdaq listing or SEC reporting, but the company warns there is no assurance it will regain compliance and its stock could be delisted. CytoSorbents is monitoring its share price and is considering options to address the deficiency, including a possible reverse stock split.

Positive

• None.

Negative

• Ongoing Nasdaq listing risk: CytoSorbents remains out of compliance with Nasdaq’s $1.00 minimum bid price rule despite receiving an extension to September 28, 2026, and explicitly states there is no assurance it will regain compliance or avoid potential delisting.

Insights

Equity listing & market structure analyst

Nasdaq grants more time, but delisting risk for CytoSorbents remains.

Nasdaq’s Listing Qualifications Staff granted CytoSorbents a further 180 days, until September 28, 2026, to meet the $1.00 minimum bid price requirement. Compliance is restored if the stock trades at or above $1.00 for at least 10 consecutive trading days.

The company previously had a deadline of March 31, 2026 following an initial non‑compliance notice dated October 2, 2025. Management is evaluating options, explicitly including a potential reverse stock split, but clearly notes there is no assurance of regaining compliance or avoiding a Nasdaq delisting.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Key Figures

Extension length: 180 days Minimum bid price: $1.00 per share New compliance deadline: September 28, 2026 +3 more

6 metrics

Extension length 180 days Additional compliance period granted by Nasdaq Listing Qualifications Staff

Minimum bid price $1.00 per share Nasdaq Listing Rule 5550(a)(2) requirement for continued listing

New compliance deadline September 28, 2026 Date by which CytoSorbents must regain minimum bid compliance

Trading days needed at $1.00+ 10 consecutive trading days Condition to regain compliance with the minimum bid rule

Initial non-compliance notice date October 2, 2025 Nasdaq letter citing 30 consecutive days below $1.00

Prior compliance deadline March 31, 2026 End of the first 180-day grace period under Rule 5810(c)(3)(A)

Key Terms

Minimum Bid Price Requirement, Nasdaq Listing Rule 5550(a)(2), Nasdaq Listing Rule 5810(c)(3)(A), Listing Qualifications Staff, +1 more

5 terms

Minimum Bid Price Requirement financial

"to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

Nasdaq Listing Rule 5550(a)(2) regulatory

"for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2)"

Nasdaq Listing Rule 5810(c)(3)(A) regulatory

"in accordance with Nasdaq Listing Rule 5810(c)(3)(A)"

Listing Qualifications Staff regulatory

"received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC"

Listing qualifications staff are the exchange employees who review and monitor whether a company meets the rules required to be listed on a stock exchange, similar to referees checking that players follow the game’s rules. They assess financial filings, corporate governance, and ongoing disclosures, and can flag problems, request corrective steps, or recommend suspension or delisting. Investors care because their determinations affect a company’s ability to trade publicly and can signal increased risk or regulatory trouble.

reverse stock split financial

"These options include, but are not limited to, effecting a reverse stock split, if necessary."

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CytoSorbents (CTSO) announce about its Nasdaq listing status?

CytoSorbents received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price rule. The extension runs until September 28, 2026, and there is currently no immediate impact on its listing or SEC reporting obligations.

What does CytoSorbents (CTSO) need to do to regain Nasdaq bid price compliance?

To regain compliance, CytoSorbents’ common stock must close at $1.00 per share or more for at least 10 consecutive trading days before September 28, 2026. Achieving this trading pattern would satisfy Nasdaq Listing Rule 5550(a)(2) on minimum bid price.

Why was CytoSorbents (CTSO) originally found non-compliant with Nasdaq rules?

Nasdaq’s staff notified CytoSorbents on October 2, 2025, that the company was not compliant because its closing bid price had been below $1.00 for 30 consecutive business days. An initial 180-day grace period ran until March 31, 2026, before the current extension was granted.

What options is CytoSorbents (CTSO) considering to address the Nasdaq deficiency?

CytoSorbents intends to keep monitoring its share price and is considering available options to resolve the deficiency. The company specifically mentions that these options include, but are not limited to, effecting a reverse stock split if necessary to meet the minimum bid requirement.

Does the Nasdaq extension change CytoSorbents’ (CTSO) current trading status?

The extension has no immediate effect on the listing of CytoSorbents’ common stock on Nasdaq or its SEC reporting. However, the company cautions there can be no assurance it will regain compliance or that its stock will not ultimately be delisted from Nasdaq.

What happens if CytoSorbents (CTSO) fails to meet the $1.00 bid price by September 28, 2026?

If CytoSorbents does not regain compliance by having its stock close at or above $1.00 for 10 consecutive trading days by September 28, 2026, its common stock may be subject to delisting from Nasdaq under the minimum bid price rule, as the company explicitly notes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 07:00 AM Learn about SEC filing dates

false 0001175151 0001175151 2026-04-01 2026-04-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 1, 2026

Cytosorbents Corporation

(Exact name of registrant as specified in its charter) 

Delaware		001-36792		98-0373793
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

305 College Road East Princeton, New Jersey		08540
(Address of principal executive offices)		(Zip code)

Registrant’s telephone number, including area code (973) 329-8885

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	CTSO	The NASDAQ Stock Market LLC (Nasdaq Capital Market)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On April 1, 2026, CytoSorbents Corporation, a Delaware corporation (the “Company”), received a letter (the “Extension Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension, or until September 28, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time prior to September 28, 2026, the bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), closes at $1.00 per share or more for a minimum of 10 consecutive trading days, the Company will regain compliance with the Minimum Bid Price Requirement. The Extension Notice has no immediate effect on the listing of the Common Stock on Nasdaq and does not affect the Company’s reporting requirements with the Securities and Exchange Commission (the “SEC”).

As previously disclosed on its Current Report on Form 8-K filed with the SEC on October 3, 2025, the Company received a letter on October 2, 2025, from the Staff indicating that, based upon the closing bid price of the Common Stock, for the preceding 30 consecutive business days, the Company was not in compliance with the Minimum Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until March 31, 2026, to regain compliance with the Minimum Bid Price Requirement.

The Company intends to continue actively monitoring the bid price for its Common Stock between now and September 28, 2026, and to continue considering available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement. These options include, but are not limited to, effecting a reverse stock split, if necessary. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the additional 180-day compliance period or that the Company’s Common Stock will not be delisted from Nasdaq.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 2, 2026	CYTOSORBENTS CORPORATION
	By:	/s/ Dr. Phillip P. Chan
	Name:	Dr. Phillip P. Chan
	Title:	Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.0 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB